Cara Therapeutics Q4 2023 Adj EPS $(0.590) Misses $(0.410) Estimate, Sales $3.000M Miss $9.421M Estimate
Portfolio Pulse from Benzinga Newsdesk
Cara Therapeutics (NASDAQ:CARA) reported Q4 2023 adjusted EPS of $(0.590), missing the $(0.410) estimate, and sales of $3.000M, missing the $9.421M estimate. This represents a 8.00% decrease in sales compared to the same period last year.
March 04, 2024 | 9:02 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cara Therapeutics reported a significant miss in both EPS and sales for Q4 2023, with a year-over-year decrease in sales.
The significant miss in both EPS and sales expectations, coupled with a year-over-year decrease in sales, is likely to negatively impact investor sentiment and the stock price of Cara Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100